RayStation to Replace Existing Treatment Planning System at NYU Langone Hospital – Long Island

RaySearch Laboratories AB (publ) announces that New York University (NYU) Langone Hospital – Long Island in Mineola, New York, has placed an order for the treatment planning system RayStation®*. The hospital is equipped with Varian linear accelerators, Accuray CyberKnife® and Accuray Radixact® systems, all of which are RayStation compatible.

The installation will provide NYU with advanced automation tools using machine learning techniques for efficient segmentation. Contingency in the clinic will also be enhanced by the feature fallback planning which ensures that alternative treatment plans are available in case a specific machine is not available. Other key RayStation features which will be implemented include multi-criteria optimization, deformable registration, and adaptive treatment planning.

Dr. Matthew Witten, PhD, the Chief Physicist in the Department of Radiation Oncology at NYU Langone Hospital – Long Island, and Director of the hospital’s Division of CyberKnife Radiosurgery says: “We seek to continually implement new technologies in the Department of Radiation Oncology at NYU. RayStation will provide a unified solution for treatment planning across all modalities, including conventional linear accelerators, CyberKnife, Radixact, and high-dose rate brachytherapy. Our goal is to make our department even more efficient, and to further our ability to provide world-class care for our patients.”

Johan Löf, founder and CEO of RaySearch, says: “We are pleased to help NYU Langone – Long Island to enhance treatment quality and efficiency by implementing RayStation for all their treatment techniques and machines.”

Revenue from the order will be recognized in the second quarter of 2023.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”